This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Phil Leighton, PhD
Director of Molecular Biology at Ligand Pharmaceuticals

Profile

Dr. Leighton is Director of Molecular Biology at Ligand Pharmaceuticals in Emeryville, CA. He received his Ph.D in Molecular Biology from Princeton University, followed by post-doctoral studies at the University of California, San Francisco. At Ligand, he has been responsible for the development and validation of lines of transgenic chickens used for the discovery of human antibodies. The original transgenic platform, OmniChickenTM, has been used for antibody discovery programs by pharmaceutical industry partners since 2016. More recently, he has developed the OmniClic line, which can be used for discovery of antibodies with a common light chain for bispecific antibody development.

Agenda Sessions

  • OmniClic: Transgenic Chickens Producing Human Antibodies for Bispecifics

    8:45am
  • OmniClic: Transgenic Chickens Producing Human Antibodies for Bispecifics

    On Demand